Edwards Lifesciences ($EW) subpoenaed for heart monitor

The U.S. Attorney's Office for Central California has subpoenaed Edwards Lifesciences ($EW) for documents pertaining to its heart monitor recall in 2006. The Vigilance I Monitor was recalled in June of that year and is now being investigated by the U.S. Attorney's office and the FDA. The company says it is "cooperating fully with the investigation."

Edward Lifesciences also posted its quarterly earnings report, with net earnings of 40 cents per diluted share. The revenue is lower than last year's third quarter, when the company made $73.5 million, or 63 cents per share.

- read MassDevice's coverage

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.